Abstract |
BILN-2061, a specific and potent peptidomimetic inhibitor of the HCV NS3 protease, has recently been shown to markedly lower serum hepatitis C virus (HCV)- RNA levels in patients chronically infected with HCV genotype 1 in three 2-day proof of principle studies. The aim of the current study was to assess the antiviral efficacy of BILN-2061 in patients with genotypes 2 and 3 HCV infection. The antiviral efficacy, pharmacokinetics, and tolerability of 500 mg twice-daily BILN-2061 given as monotherapy for 2 days in 10 patients chronically infected with non-genotype 1 HCV (genotype 2: n = 3; genotype 3: n =7) and minimal liver fibrosis (Ishak score 0-2) were assessed in a placebo-controlled (placebo n = 2), double-blind pilot study. HCV- RNA levels decreased by > or =1 log(10) copies/mL in 4 of 8 patients treated with BILN-2061. One patient showed a weak response of <1 log(10) copies/mL. Three of 8 treated patients showed no response. There was no correlation between baseline viral concentration or genotype and response. BILN-2061 exhibited good systemic exposure after oral administration and was well tolerated. In conclusion, the antiviral efficacy of the HCV serine protease inhibitor BILN-2061 is less pronounced and more variable in patients with HCV genotype 2 or 3 infection compared with previous results in patients with HCV genotype 1. A lower affinity of BILN-2061 for the NS3 protease of genotypes 2 and 3 HCV is most likely a major contributor to these findings.
|
Authors | Markus Reiser, Holger Hinrichsen, Yves Benhamou, Henk W Reesink, Heiner Wedemeyer, Cristina Avendano, Neus Riba, Chan-Loi Yong, Gerhard Nehmiz, Gerhard G Steinmann |
Journal | Hepatology (Baltimore, Md.)
(Hepatology)
Vol. 41
Issue 4
Pg. 832-5
(Apr 2005)
ISSN: 0270-9139 [Print] United States |
PMID | 15732092
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- BILN 2061
- Carbamates
- Macrocyclic Compounds
- NS3 protein, hepatitis C virus
- Quinolines
- Serine Proteinase Inhibitors
- Thiazoles
- Viral Nonstructural Proteins
|
Topics |
- Administration, Oral
- Adult
- Carbamates
(administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
- Double-Blind Method
- Drug Administration Schedule
- Female
- Genotype
- Hepacivirus
(genetics, isolation & purification)
- Hepatitis C, Chronic
(drug therapy, metabolism, virology)
- Humans
- Kinetics
- Macrocyclic Compounds
(administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
- Male
- Middle Aged
- Pilot Projects
- Prospective Studies
- Quinolines
(administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
- Serine Proteinase Inhibitors
(administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
- Thiazoles
(administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
- Viral Load
- Viral Nonstructural Proteins
(antagonists & inhibitors)
|